CAMP analyst estimates
CAMP4 Therapeutics (CAMP) analyst ratings, the average price target and its range, and every firm's latest call.
- 4 firms rate CAMP: 4 buy, 0 hold, 0 sell.
- The average price target is $9.75 from None analysts, from $6.00 to $15.00.
CAMP analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 23, 2026 | Raymond James | Raymond James Starts CAMP4 Therapeutics Corp (CAMP) at Strong Buy | $10.00 |
| Oct 15, 2026 | Needham | Camp4 Therapeutics initiated with a Buy at Needham | $8.00 |
| Sep 29, 2026 | Chardan Capital | Camp4 Therapeutics price target lowered to $6 from $6.50 at Chardan | $6.00 |
| Aug 14, 2026 | UBS | Camp4 Therapeutics price target raised to $15 from $12 at Piper Sandler | $15.00 |
| Jun 10, 2026 | Chardan Capital | Camp4 Therapeutics initiated with a Buy at Chardan | $6.50 |
| Oct 2, 2025 | Cantor Fitzgerald | Camp4 Therapeutics initiated with an Overweight at Cantor Fitzgerald | $7.00 |
| Nov 5, 2024 | Piper Sandler | Piper Sandler Starts CAMP4 Therapeutics Corp (CAMP) at Overweight | $18.00 |
| Nov 5, 2024 | Leerink Partners | Leerink Partners Starts CAMP4 Therapeutics Corp (CAMP) at Outperform | $17.00 |
| Aug 16, 2022 | Craig-Hallum | Craig-Hallum upgrades CalAmp to Buy, raises price target to $10 | $10.00 |
| Jun 24, 2022 | Goldman Sachs | Goldman Sachs cuts CalAmp EBITDA estimates on lower margin forecasts | $5.00 |